Growth Runs Into Margin Wall—and the Stock Is Oversold
Q2 delivered 48% revenue growth and 38% PAT growth, but margin guidance was de facto cut from 15–16% to ~12% on overcapacity and cost inflation. The market has priced in disappointment; the capex is real, but the earnings recovery timeline is unclear.
₹498.9 Cr
+48.2% YoY; -5.1% QoQ
₹34.8 Cr
+37.7% YoY; -55.9% QoQ
₹114 Cr
+156% YoY
11.69%
-37 bps YoY
The headline reads like a blowout—₹499 crore in revenue, 48% growth, PAT up 38%. But the quarter's real story is buried in the sequence: H1 profit of ₹114 crore split into an exceptional Q1 and a significantly softer Q2. The -55.9% QoQ drop in PAT is the tell. This tells us Q1 was the outlier, not a sustainable run-rate. On the margin front, the company has quietly rewritten its own expectations—from the prior guidance of 15–16% sustainable EBITDA to a new floor of ~12%. That reset, driven by overcapacity in synthetic latex and cost inflation, is the earnings miss the street is pricing.
The H1 Dynamics: Q1 Exceptional, Q2 the Normalized Margin
H1 revenue hit ₹1,025 crore (+44% YoY) with EBITDA of ₹175 crore and a 17.12% margin. Q2 alone did ₹498.9 crore in revenue but only ₹34.8 crore in PAT, implying Q2 EBITDA of ~₹58 crore at 11.69%. This means Q1 carried the lion's share: roughly ₹526 crore in revenue with ~₹117 crore in EBITDA at ~22% margin. Q1 benefited from timing and inventory gains; Q2 reflects the true normalized environment—compressed by inventory losses (1.5% acknowledged, recovery underway), raw material cost inflation, and pricing power limits in a carpet segment facing Middle East demand weakness.
Management's Claims vs. What Holds Up
Q2 revenue ₹499 Cr, 48% YoY growth
₹498.9 Cr delivered; 48.2% YoY growth confirmed
Supported
PAT ₹35 Cr, 38% YoY growth
₹34.8 Cr delivered; 37.7% YoY growth confirmed
Supported
EBITDA margin 11.69%, down 37 bps YoY
Operating margin 11.7% (OPM) confirmed; YoY compression clear
Supported
1.5% inventory loss depressed margins
Not independently verified in reported result; explanation logical but unquantified
Plausible, unverified
7% volume growth achieved in Q2
Not contradicted; consistent with 48% revenue growth amid deflation
Supported
Sustainable EBITDA margins ~12% (down from prior 15–16%)
Q2 delivered 11.69%; management de facto accepting 12% as the new target
Acknowledged; guidance cut
What Changed on This Call
Margin guidance cut from 15–16% sustainable EBITDA to ~12%
New long-term growth target: 10% CAGR over next 3–5 years (previously unquantified)
Nitrile expansion decision deferred pending margin recovery (waiting for 15%+ EBITDA before expanding)
Capex timeline unchanged: NBR on stream April '27, SBR June '27; ₹65 Cr of ₹220 Cr spent, on track
The Bull-Bear Ledger
Strong topline execution: 48% YoY revenue growth, 7% volume growth in a commodity cycle
Capex on track: ₹65 Cr spent of ₹220 Cr; April NBR and June SBR commissioning timelines firm
Capacity expansion real: ~₹600 Cr incremental revenue expected from NBR/SBR over 2–3 year ramp
Net cash position maintained at ₹30 Cr despite aggressive capex
Margin guidance de facto cut from 15–16% to ~12%; no clear path back to prior expectations
Carpet segment lagging: dependent on Middle East; structural overcapacity in synthetic latex weighs on pricing
Execution risk: NBR/SBR commissioning delay or cost overrun would derail FY28 growth story
Nitrile expansion deferred: management caution on market conditions signals limited near-term visibility
Ranked Risks for the Holder
Margin recovery timeline unclear
HighGuidance cut from 15–16% to ~12%; no committed path back. If margins stay at 11–12% through FY28, capex returns will disappoint.
Carpet segment structural weakness
HighDependent on Middle East/MENA demand; overcapacity post-COVID still suppressing pricing. Volume loss despite price recovery.
Capex execution and cost inflation
Medium₹220 Cr capex timeline (April–June '27) is firm, but cost overruns or delays would push FY28 revenue ramp and dent returns.
Synthetic latex overcapacity
MediumIndustry-wide challenge; limits pricing power. Management waiting 2–3 quarters before nitrile expansion—a sign of caution on market saturation.
Geopolitical supply chain disruptions
MediumRaw material costs and freight rates remain elevated. Pass-through has limits; margin compression continues despite volume growth.
How the Street Is Positioned
The stock is severely oversold: trading at ₹484.25, it sits below its 20-day average (₹554.69), 50-day (₹589.1), and near its 200-day (₹486.27), with RSI at 26.7—deep oversold territory. From its all-time high of ₹712, the stock is down 32%, yet it has recovered 56% from its 52-week low of ₹310.45. Volume is increasing, a sign either of capitulation or accumulation. Institutional holding remains minimal: FII at 0.69%, DII at 1.91%, promoters stable at 58.23%. The margin miss—not the revenue beat—is driving the repricing. The market is telling you it doesn't believe the 12% margin floor, much less a recovery to 15–16%. This gap between fundamentals (capex real, revenue growth solid) and sentiment (margins cut, execution uncertain) is where the tension lies for the next 2–3 quarters.
What to Watch Next
1 · H2 FY27 EBITDA margin
Management expects inventory losses to normalize and prices to stabilize as the year progresses. If H2 margins track above 12.5%, the recovery narrative gains credibility. Below 11%, the 12% floor becomes a concern.
2 · NBR commissioning and ramp-up (April 2027)
₹65 Cr of ₹220 Cr capex is spent; timelines are firm. Watch for any delay signals or cost overrun disclosures in Q3/Q4 filings. On-time, on-budget commission confirms execution.
3 · Carpet segment recovery or pivot
Middle East demand is the near-term headwind. If domestic or Southeast Asian substitution begins to offset MENA weakness by H1 FY28, the largest risk (segment rotation) is mitigated.
APCOTEX is delivering on its topline and capex promises, but margin compression is the honest read on Q2. This is not a step-change—it's a steady execution story hampered by cyclical headwinds and industry overcapacity. The stock is priced as if the capex will deliver mediocre returns; the oversold levels suggest the market is waiting for proof of margin recovery. That proof comes from H2 FY27 and the ramp trajectory in FY28. Until then, this is a medium-risk hold—the capex is real, but the earnings recovery timeline is unclear.
The number to track from here is the H2 EBITDA margin. If it sustains above 12.5%, the 10% CAGR growth story becomes credible. Below 11%, margin pressure persists and the capex returns are at risk.
Informational and educational content only. Not investment advice.